samedan logo

 
 
spacer
home > ict > autumn 2019 > the pacific rim
PUBLICATIONS
International Clinical Trials

The Pacific Rim





In the US and EU, approximately 35% of trial delays occur as a result of patient recruitment, and one-fifth of the trials in these countries do not enrol a sufficient number of subjects. Shown in Figure 1, to expedite the recruitment process and avoid drug approval delays, both the US and EU have increased their number of registered clinical trials in developed Asian countries such as Japan, South Korea, China, India, and Malaysia (1).

It is well known that the primary barriers to conducting clinical trials in the US and Western Europe involve challenges in participant recruitment and retention, resulting in longer lead times and high costs (2). Furthermore, contracting qualified and experienced investigators and key opinion leaders add to the already lengthy trial times (3).

A 2013 analysis found that almost 57% of trials fail due to low patient accrual rates, which could translate into huge financial losses (4). Adding to this recruitment problem, racial and ethnic minorities, women, and the elderly are often under-represented in enrolments. For example, a study found that only 25% of elderly cancer patients enrol in trials, although they account for 63% of new cancer cases (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author

As Chief Medical Officer of Linical Accelovance Group, Dr Tracy Goeken is responsible for providing strategic and operational leadership regarding the company’s global medical and scientific operations. Dr Goeken oversees clinical development functions and activities within the company, including medical, regulatory, medical writing, and pre- and post-market pharmacovigilance departments ensuring global alignment and operational excellence. Tracy received his MD from St. Christopher’s College of Medicine, UK, having completed his clinical training at LSU Health Sciences Center in Louisiana.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Unveils its full Conference Line-up for SCOPE 2020

PHILADELPHIA, PA – February 11, 2020: The SCOPE Summit for Clinical Operations Executives annually convenes innovative thought leaders from across the life sciences industry to share ideas, challenges and best practices that will help drive change and improve patient centricity throughout the coming year and beyond. Subject matter experts from Signant Health will host and participate in key discussions on the importance of eConsent and patient engagement, the impact of data analytics on endpoint quality, and how to integrate sensors and wearables into eCOA trials as part of the patient journey through clinical research.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement